Browsing by Author "Aruna Agarwal"

Now showing 1 - 2 of 2

Development and validation of a RP-HPLC method for the simultaneous determination of Mangiferin, Ellagic acid and Hydroxycitric acid in polyherbal formulation
(EManuscript Services, 2014) Ananth Kumar Kammalla; Mohan Kumar Ramasamy; Aruna Agarwal; G.P. Dubey; Kaliappan Ilango
The US patented polyherbal formulation for the prevention and management of Type II diabetes and its vascular complications was used for the present study. The formulation consists of roots of Salacia species, leaves of Lagestroemia parviflora and fruit rind of Garcinia indica. The use of reversed phase C18 HPLC column was used and eluted with isocratic mobile phase of acetonitrile and phosphoric acid buffer solution enabled the efficient separation of chemical markers within 20min. Validation of the method was performed in order to demonstrate its selectivity, accuracy, precision, repeatability and recovery. All calibration curve shows good linear correlation coefficients (r2>0.995) within tested ranges. Three markers in this polyherbal formulation were quantified were Mangiferin (1.53% w/w), Ellagic acid (0.9655 w/w), Hydroxycitric acid (5.3% w/w). Intra and inter day RSDs of retention times and peak areas were less than 3%. The recoveries were between 95% and 102.5%. In conclusion a method has been developed for the simultaneous quantification of three markers in this polyherbal formulation. The established RP-HPLC method was simple, precise and accurate and can be used for the quality control of the raw materials as well as formulations.
Nephroprotective role of salacia chinensis in diabetic CKD patients: A pilot study
(2010) Rana G. Singh; Surendra S. Rathore; Rajesh Kumar; Usha; Aruna Agarwal; Govind P. Dubey
Background: Present study aimed to study effect of Salacia Chinensis, a herbal drug, on stabilization of renal functions, and markers of endothelial dysfunction in diabetic chronic kidney disease (CKD) patients. Materials and Methods: 30 stable diabetic CKD patients were randomized into 2 groups; group A and B of 15 patients each. Group A was given trial drug Salacia chinensis 1000 mg twice-daily while group B received placebo. Measures of renal function: Serum creatinine and creatinine clearance; markers of endothelial dysfunction: Interleukin-6 and serum Homocysteine, and lipid profile were measured at baseline and during follow-up period of 6 months. Results : There was stabilization of renal function as measured by serum creatinine and creatinine clearance in patients who received Salacia Chinensis compared to placebo (P value < 0.05), suggesting that Salacia chinensis may retard the progression of chronic kidney disease. Similarly, there was significant decline in both serum homocysteine and IL-6 levels. [P value < 0.05 for both]. Conclusion: This pilot study showed a promising role for Salacia chinensis as a renoprotective drug, but further prospective studies involving large number of patients are needed to confirm this and also to delineate possible mechanisms.